# Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

> **NCT00957918** · PHASE1,PHASE2 · COMPLETED · sponsor: **Neuraltus Pharmaceuticals, Inc.** · enrollment: 65 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** nicotine
- **OTHER:** placebo comparator

## Key facts

- **NCT ID:** NCT00957918
- **Lead sponsor:** Neuraltus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2011-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00957918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00957918, "Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00957918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*